The Valley Desk

NCT04448886 · Interventional trial

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Overall registry status Active not recruiting

Phase 2

Conditions HER2-negative Breast Cancer, HR-Positive Breast Cancer, Invasive Breast Cancer, Metastatic Breast Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov